Flag tagged CD19-CAR-T cells
US11034763B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 1, 2018 |
| Grant date | Jun 15, 2021 |
| Priority date | — |
| Expiry date | Mar 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/43
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides chimeric antigen receptor (CAR)-T cells modified to express a CAR fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen CD19, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the fusion protein further comprises a FLAG tag N-terminus to scFv, C-terminus to scFv, or between VH and VL. Using CD19-FLAG CAR-T cells instead of CD19 CAR-T cells, cytokine levels (Interferon-γ, IL-2 and IL6) caused by infused CAR-T cells are reduced.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.